Dendritic Cells in Cancer: Emergenceof the Discipline

Shurin, Michael R.; Lotze, Michael T.

doi:10.1007/978-0-387-88611-4_2

Cited by 3 publications

(2 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several different tumor-derived factors, including gangliosides, neuropeptides, NO and other molecules may decrease longevity of DCs 50. For instance, MUC2 mucins purified from the conditioned medium of a colorectal cancer cell line were reported to increase the number of apoptotic cells in human monocyte-derived DC cultures, which was partially mediated by the ligation of the MUC2 mucins with Siglec-3 on DCs 51.…”

Section: Tumor-induced Apoptosis Of Dendritic Cellsmentioning

confidence: 99%

Dendritic Cells in the Cancer Microenvironment

Shurin²,

et al. 2013

Self Cite

View full text Add to dashboard Cite

The complexity of the tumor immunoenvironment is underscored by the emergence and discovery of different subsets of immune effectors and regulatory cells. Tumor-induced polarization of immune cell differentiation and function makes this unique environment even more intricate and variable. Dendritic cells (DCs) represent a special group of cells that display different phenotype and activity at the tumor site and exhibit differential pro-tumorigenic and anti-tumorigenic functions. DCs play a key role in inducing and maintaining the antitumor immunity, but in the tumor environment their antigen-presenting function may be lost or inefficient. DCs might be also polarized into immunosuppressive/tolerogenic regulatory DCs, which limit activity of effector T cells and support tumor growth and progression. Although various factors and signaling pathways have been described to be responsible for abnormal functioning of DCs in cancer, there are still no feasible therapeutic modalities available for preventing or reversing DC malfunction in tumor-bearing hosts. Thus, better understanding of DC immunobiology in cancer is pivotal for designing novel or improved therapeutic approaches that will allow proper functioning of DCs in patients with cancer.

show abstract

Section: Tumor-induced Apoptosis Of Dendritic Cellsmentioning

confidence: 99%

Dendritic Cells in the Cancer Microenvironment

Shurin²,

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…In particular, even the appropriate DC subset for clinical use remains undefined. Given the functional differences among DC subsets, further understanding of the biology of each DC subset in the complex tumor-associated environment is crucial (Shurin and Lotze 2009; Ueno et al 2010). …”

Section: Introductionmentioning

confidence: 99%

Langerhans Cells from Human Cutaneous Squamous Cell Carcinoma Induce Strong Type 1 Immunity

Fujita

Suárez‐Fariñas

Mitsui

et al. 2012

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Purpose Langerhans cells [LCs] are dendritic cells [DCs] localized to the epidermis. They should be the first antigen presenting cells to encounter squamous cell carcinoma (SCC). The aim of this study was to investigate the ability of LCs isolated from human SCC to induce T cell proliferation and polarization. Experimental design We investigated the ability of LCs from SCC and peritumoral skin to induce T-cell proliferation and polarization. We also studied the effect of SCC supernatant on the ability of LCs from normal skin, in vitro generated LCs, and DCs to activate and polarize T cells. Results LCs from SCC were stronger inducers of allogeneic CD4+ and CD8+ T-cell proliferation and interferon (IFN)-γ production than LCs from peritumoral skin. We found that tumor supernatants were rich in immunosuppressive cytokines; despite this, allogeneic CD4+ and CD8+ T-cell proliferation and IFN-γ induction by LCs were augmented by tumor supernatant. Moreover, tumor supernatant facilitated IFN-γ induction by in vitro generated LCs, but suppressed the ability of in vitro generated DCs to expand allogeneic CD4+ and CD8+ T cells. Conclusions We have demonstrated that LCs from SCC can induce type-1 immunity. Tumor supernatant induces IFN-γ induction by in vitro generated LCs. This contrasts greatly with prior studies showing that DCs from SCC cannot stimulate T cells. These data indicate that LCs may be superior to DCs for SCC immunotherapy and may provide a novel rationale to harnessing LCs for the treatment of cancer patients.

show abstract